Dr. Lal Path Labs Ltd. — Credit Ratings, 22-04-2025: Credit Rating

On a consolidated basis, Dr. Lal Pathlabs Limited reported a total operating income (TOI) of ₹2,227 crore for the fiscal year ending March 31, 2024, reflecting a year-over-year growth of approximately 10%. This growth is attributed to an increase in patient volumes, particularly in tier-2 and tier-3 cities, alongside a slight rise in average revenue per patient, highlighting the efficacy of the company's geographical diversification strategy and robust B2C segment performance.

Net profit surged to ₹362 crore in FY24, up from ₹241 crore in the previous year, yielding an earnings per share (EPS) of ₹27.41. The improvement in profitability is supported by a strong PBILDT margin of 27.37%, up from 24.66% in FY23, driven by operational efficiencies and a favorable mix of services post-COVID-19.

Operational costs have stabilized, but the company faces challenges in a fragmented industry with increasing competition, particularly as it takes on the operational complexities of its recent acquisition, Suburban Diagnostics India Private Limited, which is currently underperforming in profitability.

The balance sheet remains healthy, showing a sharp reduction in overall gearing to 0.13x, alongside strong debt coverage indicators with an interest coverage ratio of 20.76 times. This solid financial foundation lends itself well to future growth strategies, which may include further geographic and service diversification.

Given the favorable demand outlook for the Indian diagnostics industry, expected to grow at double-digit rates, and DLPL's strong liquidity profile, the company presents a compelling case for a buy. Investors should monitor ongoing competitive pressures and the integration of acquisitions, which may introduce risks that could impact profitability.